Cidara Therapeutics, Inc. (CDTX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CDTX Revenue Growth
Revenue Breakdown (FY 2024)
CDTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CDTX Revenue Analysis (2013–2024)
As of May 6, 2026, Cidara Therapeutics, Inc. (CDTX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, CDTX's 5-year compound annual growth rate (CAGR) stands at -42.9%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $64.4 million in 2022.
Revenue diversification analysis shows CDTX's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ACAD (+12.7% YoY), AGIO (+78.3% YoY), and ENTA (+0.6% YoY). Compare CDTX vs ACAD →
CDTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CDTXCurrent | $0 | - | -42.9% | -13811.9% | |
 ACAD | $958M | +12.7% | +23.1% | 24.1% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 ENTA | $65M | +0.6% | -11.8% | -130.7% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% |
CDTX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.3M | -94.5% | $1.3M | 100.0% | $-176,102,000 | -13811.9% |
| 2023 | $23.3M | -63.9% | $-13,480,000 | -57.9% | $-27,060,000 | -116.2% |
| 2022 | $64.4M | +30.0% | $64.4M | 100.0% | $-33,503,000 | -52.0% |
| 2021 | $49.6M | +310.8% | $-23,515,000 | -47.4% | $-42,255,000 | -85.2% |
| 2020 | $12.1M | -42.3% | $12.1M | 100.0% | $-71,849,000 | -595.4% |
| 2019 | $20.9M | - | $-25,486,000 | -121.9% | $-41,724,000 | -199.5% |
| 2018 | $0 | - | $-523,000 | - | $-63,285,000 | - |
| 2017 | $0 | - | $-667,000 | - | $-55,721,000 | - |
| 2016 | $0 | - | $-732,000 | - | $-48,436,000 | - |
| 2015 | $0 | - | $-461,000 | - | $-32,313,000 | - |
See CDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CDTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CDTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCDTX — Frequently Asked Questions
Quick answers to the most common questions about buying CDTX stock.
Is CDTX's revenue growth accelerating or slowing?
CDTX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: -42.9%.
What is CDTX's long-term revenue growth rate?
Cidara Therapeutics, Inc.'s 5-year revenue CAGR of -42.9% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CDTX's revenue distributed by segment?
CDTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.